Claritas Rx is featured in the BioXconomy article, “Claritas Rx launches data platform boosting specialty drug first fill rates” for the launch of our new integrated data and consent solution for specialty and rare brands.
The article highlights how our Foundational Data Aggregation and Consent Clearinghouse™ is helping manufacturers drive higher first fill rates and long-term persistence by unifying fragmented data into a trusted, analytics-ready view of the patient journey. If you’re working to understand patient consent, reduce abandonment, or get a clearer view of what’s really happening across your access ecosystem, this is a great overview of what’s possible.
At a Glance
- Platform achieves over 95% match rates across patients, healthcare providers and payer databases
- AI assistant answers complex pharmacy questions in real time to accelerate patient care decisions
- Consent Clearinghouse centralizes patient permissions in a secure, HIPAA-compliant environment
The solution, detailed in the newly released white paper titled “Transforming Data Aggregation in Specialty and Rare Disease,” offers commercial, patient services, and data teams a comprehensive view of the specialty patient journey. By integrating data from multiple sources and making it analytics-ready, the platform addresses long-standing challenges in specialty and rare disease care.
